Why Credit Suisse Just Upgraded St. Jude Medical

Loading...
Loading...
In a report published Monday, Credit Suisse analysts upgraded
St Jude Medical, Inc.STJ
from Underperform to Neutral. The analysts expect the share price gains witnessed by
Medtronic plcMDT
to diminish by mid-2015, while expecting upside to CardioMEMS sales in the long-term. "While we expect CardioMEMS sales to be in line with guidance this year we see long-term upside based on our recently published survey. Moreover we expect Atrial Fibrillation & Neuromodulation to gain momentum over the course of the year, leaving around 5% CC sales growth after adjusting for missed selling days," the analysts said. Credit Suisse has also forecasted top-line acceleration for St Jude to close to 3.9 percent in FY15 from 2.0 percent in FY13, on the back of continued traction from FFR & OCT as well as new product launches. In fact, there could be further upside to the estimates in the longer-term if CardioMEMS witnesses stronger-than-anticipated uptake. "We currently forecast $77M in 2015 CardioMEMS sales vs. guidance of $70M, but note that the Street's anticipation for 2016 CardioMEMs sales will be determinative for the stock in the 2H of 2015," the analysts added. However, the sales/EPS estimates for FY15 revised down due to worsening foreign exchange rates.
Loading...
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorUpgradesAnalyst RatingsCredit Suisse
We simplify the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...